Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion

Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wewer Albrechtsen, Nicolai J., Veedfald, Simon, Plamboeck, Astrid, Deacon, Carolyn F., Hartmann, Bolette, Knop, Filip K., Vilsboll, Tina, Holst, Jens J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709665/
https://www.ncbi.nlm.nih.gov/pubmed/26839899
http://dx.doi.org/10.1155/2016/8352957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709665/
https://www.ncbi.nlm.nih.gov/pubmed/26839899
http://dx.doi.org/10.1155/2016/8352957

Ejemplares similares